These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 26816019)

  • 1. Antiretroviral Therapy in Early HIV Infection.
    Lundgren J; Babiker AG; Neaton JD
    N Engl J Med; 2016 Jan; 374(4):394. PubMed ID: 26816019
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiretroviral Therapy in Early HIV Infection.
    Lopez-Cortes LF; Gutiérrez-Valencia A; Ben-Marzouk-Hidalgo OJ
    N Engl J Med; 2016 Jan; 374(4):393. PubMed ID: 26816020
    [No Abstract]   [Full Text] [Related]  

  • 3. Antiretroviral Therapy in Early HIV Infection.
    Corrao S; Prestileo T; Di Lorenzo F
    N Engl J Med; 2016 Jan; 374(4):393-4. PubMed ID: 26816021
    [No Abstract]   [Full Text] [Related]  

  • 4. In early HIV infection, immediate vs deferred antiretroviral therapy reduced serious illnesses at 3 years.
    Smaill F
    Ann Intern Med; 2015 Dec; 163(12):JC4. PubMed ID: 26666806
    [No Abstract]   [Full Text] [Related]  

  • 5. Antiretroviral therapy for HIV should be started at diagnosis regardless of CD4+ count, study concludes.
    Wise J
    BMJ; 2015 Jul; 351():h3943. PubMed ID: 26198644
    [No Abstract]   [Full Text] [Related]  

  • 6. [HIV-infection: Early therapy is beneficial].
    Seybold U
    Dtsch Med Wochenschr; 2015 Sep; 140(18):1338. PubMed ID: 26360940
    [No Abstract]   [Full Text] [Related]  

  • 7. In HIV-1, immediate vs deferred antiretroviral therapy and isoniazid vs no isoniazid reduced severe illness at 30 mo.
    Smaill F
    Ann Intern Med; 2015 Dec; 163(12):JC5. PubMed ID: 26666807
    [No Abstract]   [Full Text] [Related]  

  • 8. Initiating antiretroviral therapy in HIV-infected patients with >500 CD4 cells/µL provides more benefit than delaying treatment.
    Rutherford GW; Anglemyer A
    Evid Based Med; 2016 Feb; 21(1):26. PubMed ID: 26660663
    [No Abstract]   [Full Text] [Related]  

  • 9. Overcoming Impediments to Global Implementation of Early Antiretroviral Therapy.
    Abdool Karim SS
    N Engl J Med; 2015 Aug; 373(9):875-6. PubMed ID: 26193047
    [No Abstract]   [Full Text] [Related]  

  • 10. A tinea immune reconstitution inflammatory syndrome in a HIV-positive patient starting combination antiretroviral treatment.
    Lupia T; Costa C; Forni N; Calcagno A
    G Ital Dermatol Venereol; 2020 Oct; 155(5):695-697. PubMed ID: 30636396
    [No Abstract]   [Full Text] [Related]  

  • 11. Antiretroviral vaginal gel shows promise against HIV.
    Baleta A
    Lancet; 2010 Jul; 376(9738):320. PubMed ID: 20681062
    [No Abstract]   [Full Text] [Related]  

  • 12. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.
    ; Lundgren JD; Babiker AG; Gordin F; Emery S; Grund B; Sharma S; Avihingsanon A; Cooper DA; Fätkenheuer G; Llibre JM; Molina JM; Munderi P; Schechter M; Wood R; Klingman KL; Collins S; Lane HC; Phillips AN; Neaton JD
    N Engl J Med; 2015 Aug; 373(9):795-807. PubMed ID: 26192873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracavitary primary effusion lymphoma (PEL) presenting as bilateral adrenal gland involvement in an HIV-positive patient.
    Nabergoj M; Nawej Tshikung O; Tsopra O; Ghinescu A; Samii K; Calmy A
    Ann Hematol; 2019 May; 98(5):1317-1318. PubMed ID: 30328487
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion.
    Hocqueloux L; Saez-Cirion A; Rouzioux C
    JAMA Intern Med; 2013 Mar; 173(6):475-6. PubMed ID: 23529554
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion--reply.
    Porter K; Lodi S; Meyer L
    JAMA Intern Med; 2013 Mar; 173(6):476-7. PubMed ID: 23529555
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacogenetic testing for the treatment of aspergillosis with voriconazole in two HIV-positive patients.
    Fulco PP; Beaulieu C; Higginson RT; Bearman G
    Pharmacogenet Genomics; 2019 Aug; 29(6):155-157. PubMed ID: 31211761
    [No Abstract]   [Full Text] [Related]  

  • 17. Both improvement and worsening of adherence to antiretroviral treatment can be expected while transitioning HIV-positive adolescents to adult health care.
    Kowalska JD; Popielska J; Wroblewska A; Firląg-Burkacka E; Horban A; Marczyńska M
    Infect Dis (Lond); 2019 Jun; 51(6):463-466. PubMed ID: 30856034
    [No Abstract]   [Full Text] [Related]  

  • 18. [Adherence, pharmacokinetic "tolerance capacity" and HIV resistance development].
    Mossdorf E; Hirsch HH
    Praxis (Bern 1994); 2006 Aug; 95(33):1237-9. PubMed ID: 16939126
    [No Abstract]   [Full Text] [Related]  

  • 19. For human immunodeficiency virus disease, more treatment seems to be better: comment on "Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion".
    Katz MH
    Arch Intern Med; 2012 Sep; 172(16):1256. PubMed ID: 22824829
    [No Abstract]   [Full Text] [Related]  

  • 20. Achieving South Africa's National Strategic Plan for HIV/AIDS.
    Williams BG; Ginsburg D; Montaner J; Stander T; Welte A
    Lancet; 2009 Mar; 373(9667):895-6. PubMed ID: 19286085
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.